Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00097227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Study identification
- NCT ID
- NCT00097227
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 165 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2004 (Type not available)
- Primary completion
- Apr 2007 (Actual)
- Completion
- Apr 2007 (Actual)
- Last update posted
- Apr 9, 2010
2004 – 2007
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Los Angeles | California | 90089 | — |
| ImClone Investigational Site | Santa Monica | California | 90404 | — |
| ImClone Investigational Site | Newark | Delaware | 19713 | — |
| ImClone Investigational Site | Orlando | Florida | 32804 | — |
| ImClone Investigational Site | St. Petersburg | Florida | 33705 | — |
| ImClone Investigational Site | Tucker | Georgia | 30084 | — |
| ImClone Investigational Site | Terra Haute | Indiana | 47804 | — |
| ImClone Investigational Site | Louisville | Kentucky | 40202 | — |
| ImClone Investigational Site | Baltimore | Maryland | 21204 | — |
| ImClone Investigational Site | Ypsilanti | Michigan | 48197 | — |
| ImClone Investigational Site | Newark | New Jersey | 07112 | — |
| ImClone Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| ImClone Investigational Site | Philadelphia | Pennsylvania | 19141 | — |
| ImClone Investigational Site | Columbia | South Carolina | 29209 | — |
| ImClone Investigational Site | Knoxville | Tennessee | 37920 | — |
| ImClone Investigational Site | Houston | Texas | 77024 | — |
| ImClone Investigational Site | Temple | Texas | 76508 | — |
| ImClone Investigational Site | Richmond | Virginia | 23230 | — |
| ImClone Investigational Site | Tacoma | Washington | 98405 | — |
| ImClone Investigational Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00097227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2010 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00097227 live on ClinicalTrials.gov.